XML 32 R18.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders' Equity
 6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
On November 5, 2025, the Company’s Board of Directors approved a Share Repurchase Program (the "Share Repurchase Program") of up to $15,000,000 of its common stock. Under the Share Repurchase Program, the Company may repurchase shares through open market transactions, through privately negotiated transactions, or pursuant to a trading plan separately adopted in the future, subject to the requirements of the Securities Exchange Act of 1934, as amended. The Share Repurchase Program has no set expiration date, and may be suspended, modified or discontinued at any time.

A summary of the Company’s common stock that has been repurchased as part of the Share Repurchase Program for the three and six months ended June 30, 2026 is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in thousands, except per share data)
Shares repurchased74 — 74 — 
Average price per share$27.11 $— $27.11 $— 
Total investment$1,993 $— $1,993 $— 

As of June 30, 2026, the Company had approximately $10,021,000 of remaining authorization for purchases under the Share Repurchase Program.

In January 2019, the Company’s board of directors adopted the 2019 Stock Incentive Plan (the "Plan"). As of June 30, 2026, a total of 1,136,267 shares of common stock were available for further award grants under the Plan. For the three months ended June 30, 2026 and 2025, the Company recognized a total of $596,000 and $445,000 in stock-based compensation expense, respectively. For the six months ended June 30, 2026 and 2025, the Company recognized a total of $838,000 and $791,000 in stock-based compensation expense, respectively. The Company recognizes stock-based compensation over the vesting period, which is generally within three years for both the restricted stock units and stock options.

Stock Options

A summary of the Company’s stock option activity under the Plan for the six months ended June 30, 2026 is as follows:
Number of Options
Weighted-Average Exercise Price
Weighted-Average Remaining Contract Life
Aggregate Intrinsic Value
(in years)
(in thousands)
Outstanding at December 31, 2025287,467 $18.56 5.8$1,152 
Exercised(1,600)18.86 
Outstanding at June 30, 2026285,867 $18.56 5.3$4,259 
Vested and expected to vest at June 30, 2026285,867 $18.56 5.3$4,259 
Exercisable at June 30, 2026285,867 $18.56 5.3$4,259 
There were no stock options granted or forfeited during the six months ended June 30, 2026. At June 30, 2026, all stock options granted under the Plan were fully vested and exercisable.

The aggregate intrinsic value is calculated by subtracting the exercise price of the option from the closing price of the Company’s common stock on June 30, 2026 and December 31, 2025, respectively, multiplied by the number of shares per each option.

Restricted Stock Units

A summary of the Company’s unvested restricted stock units' activity under the Plan for the six months ended June 30, 2026 is as follows:
Number of Shares Outstanding
Weighted Average Grant Date Fair Value
Unvested at December 31, 202543,500 $28.53 
Granted141,250 23.92 
Vested(32,500)29.27 
Unvested at June 30, 2026152,250 $24.10 
At June 30, 2026, total remaining stock-based compensation cost for unvested restricted stock units was approximately $2,842,000. The cost is expected to be recognized over a weighted-average period of 1.5 years.